Clinical Outcomes by Tumor Mutational Burden and Inflammatory Gene Expression With Combined Nivolumab and Ipilimumab or Monotherapy in Advanced Melanoma - CM066-WES
Purpose Exploratory analyses of CheckMate 066 and 067 trials were conducted to investigate associations of tumor mutational burden (TMB), a 4-gene inflammatory gene expression signature, and BRAF mutation status with tumor response, progression-free survival (PFS), and overall survival (OS) in patients with advanced melanoma. Patients and Methods Patients with known programmed death ligand 1 (PD-L1) expression and BRAF mutation status received nivolumab (NIVO) or dacarbazine in CheckMate 066 and either NIVO, ipilimumab (IPI), or NIVO+IPI in CheckMate 067. Whole exome sequencing and RNA sequencing were used to determine TMB and inflammatory gene expression signature scores, respectively. These biomarkers were evaluated in terms of their association with PFS and OS. Results In the NIVO, NIVO+IPI, and IPI arms of CheckMate 067, longer survival was associated with high (> median) versus low (≤ median) TMB with hazard ratios (HRs) (95% confidence interval [CI]) for PFS of 0.45 (0.30–0.65), 0.55 (0.38–0.81), and 0.60 (0.43–0.82), and for OS of 0.46 (0.30–0.71), 0.53 (0.34–0.82), and 0.52 (0.36–0.74), respectively. For NIVO-treated patients, these results were confirmed in CheckMate 066. A survival benefit was observed with high TMB and absence of BRAF mutation. Survival was associated with high versus low inflammatory signature scores with HRs (95% CI) for PFS of 0.56 (0.34–0.94), 0.40 (0.23–0.72), and 0.43 (0.27–0.70), and for OS of 0.37 (0.20–0.66), 0.38 (0.19–0.74), and 0.46 (0.27–0.79), in the NIVO, NIVO+IPI, and IPI arms, respectively. Weak correlations were observed between PD-L1, TMB, and the inflammatory signature. Conclusions Combined assessment of TMB, inflammatory gene expression signature, and BRAF mutation status may be predictive for response to immunotherapy in advanced melanoma.
- 32 samples
- DAC: EGAC00001001667
- Technology: Illumina HiSeq 2500
- HMB DUO:0000006 (version: 2019-01-07)health or medical or biomedical researchThis data use permission indicates that use is allowed for health/medical/biomedical purposes; does not include the study of population origins or ancestry.
- DS DUO:0000007 (version: 2019-01-07)disease specific researchThis data use permission indicates that use is allowed provided it is related to the specified disease.ModifiersMONDO:0004992 MONDO:0005105
Requests for access the BMS accession numbers in EGA should be directed to the BMS FastTrack portal - https://fasttrack.bms.com/. This externally facing website serves as BMS’ request portal for all ISRs (both clinical and non-clinical), as well as for requests for data generated as a part of a BMS study. This portal is facilitated by BMS’ Clinical Trial Transparency organization.
Purpose Below you will find general notes and tips for when you are creating an ISR Request. General Notes and Tips • * [Asterisks] indicate a required field within the interface • You will not be able to move on to the next page if a required field is not completed • Periodically click Save (located at the bottom right corner on any form) in order to save your information. If you do not have all the information, which is necessary to submit your request, click Save and a draft will be available for you on your homepage when you are ready to return to the form. The forms do not auto-save. • FastTrack has a security time-out feature. After sixty (60) minutes of inactivity, you will be required to log back into the system. o If you are working on a record and leave it open while performing other tasks, it is recommend that you navigate to the bottom of the record and click Save to prevent you from losing data you have entered • You can return to any section of the form at any point by clicking the tabs at the top of the page or clicking Back in the lower left of the page We are committed to providing you with answers to your questions and concerns. Please contact us using the information below, and we will respond to your inquiry as quickly as possible. Technical Support Main Number: +1 844-439-5499 (US only) For Outside US, please see the “International BMS Help Desk Phone Number Guide” Main Email: hd-sci-apps@bms.com
Studies are experimental investigations of a particular phenomenon, e.g., case-control studies on a particular trait or cancer research projects reporting matching cancer normal genomes from patients.
| Study ID | Study Title | Study Type |
|---|---|---|
| EGAS00001004567 | Other |
This table displays only public information pertaining to the files in the dataset. If you wish to access this dataset, please submit a request. If you already have access to these data files, please consult the download documentation.
| ID | File Type | Size | Located in | |
|---|---|---|---|---|
| EGAF00004186659 | fastq.gz | 4.8 GB | ||
| EGAF00004186660 | fastq.gz | 4.9 GB | ||
| EGAF00004186661 | fastq.gz | 4.0 GB | ||
| EGAF00004186662 | fastq.gz | 4.2 GB | ||
| EGAF00004186663 | fastq.gz | 3.6 GB | ||
| EGAF00004186664 | fastq.gz | 3.8 GB | ||
| EGAF00004186665 | fastq.gz | 3.4 GB | ||
| EGAF00004186666 | fastq.gz | 3.6 GB | ||
| EGAF00004186667 | fastq.gz | 3.2 GB | ||
| EGAF00004186668 | fastq.gz | 3.3 GB | ||
| EGAF00004186669 | fastq.gz | 3.5 GB | ||
| EGAF00004186670 | fastq.gz | 3.6 GB | ||
| EGAF00004186671 | fastq.gz | 3.6 GB | ||
| EGAF00004186672 | fastq.gz | 3.7 GB | ||
| EGAF00004186673 | fastq.gz | 3.8 GB | ||
| EGAF00004186674 | fastq.gz | 3.9 GB | ||
| EGAF00004186675 | fastq.gz | 3.3 GB | ||
| EGAF00004186676 | fastq.gz | 3.3 GB | ||
| EGAF00004186677 | fastq.gz | 4.2 GB | ||
| EGAF00004186678 | fastq.gz | 4.3 GB | ||
| EGAF00004186679 | fastq.gz | 4.3 GB | ||
| EGAF00004186680 | fastq.gz | 4.6 GB | ||
| EGAF00004186681 | fastq.gz | 4.4 GB | ||
| EGAF00004186682 | fastq.gz | 4.3 GB | ||
| EGAF00004186683 | fastq.gz | 3.2 GB | ||
| EGAF00004186684 | fastq.gz | 3.4 GB | ||
| EGAF00004186685 | fastq.gz | 3.2 GB | ||
| EGAF00004186686 | fastq.gz | 3.3 GB | ||
| EGAF00004186687 | fastq.gz | 4.0 GB | ||
| EGAF00004186688 | fastq.gz | 4.0 GB | ||
| EGAF00004186689 | fastq.gz | 3.8 GB | ||
| EGAF00004186690 | fastq.gz | 3.8 GB | ||
| EGAF00004186691 | fastq.gz | 3.9 GB | ||
| EGAF00004186692 | fastq.gz | 4.1 GB | ||
| EGAF00004186693 | fastq.gz | 5.0 GB | ||
| EGAF00004186694 | fastq.gz | 4.8 GB | ||
| EGAF00004186695 | fastq.gz | 4.6 GB | ||
| EGAF00004186696 | fastq.gz | 4.7 GB | ||
| EGAF00004186697 | fastq.gz | 3.4 GB | ||
| EGAF00004186698 | fastq.gz | 3.5 GB | ||
| EGAF00004186699 | fastq.gz | 4.2 GB | ||
| EGAF00004186700 | fastq.gz | 4.3 GB | ||
| EGAF00004186701 | fastq.gz | 3.5 GB | ||
| EGAF00004186702 | fastq.gz | 3.7 GB | ||
| EGAF00004186703 | fastq.gz | 3.7 GB | ||
| EGAF00004186704 | fastq.gz | 3.9 GB | ||
| EGAF00004186705 | fastq.gz | 4.3 GB | ||
| EGAF00004186706 | fastq.gz | 4.5 GB | ||
| EGAF00004186707 | fastq.gz | 3.4 GB | ||
| EGAF00004186708 | fastq.gz | 3.6 GB | ||
| EGAF00004186709 | fastq.gz | 4.4 GB | ||
| EGAF00004186710 | fastq.gz | 4.5 GB | ||
| EGAF00004186711 | fastq.gz | 3.4 GB | ||
| EGAF00004186712 | fastq.gz | 3.5 GB | ||
| EGAF00004186713 | fastq.gz | 4.7 GB | ||
| EGAF00004186714 | fastq.gz | 4.8 GB | ||
| EGAF00004186715 | fastq.gz | 4.2 GB | ||
| EGAF00004186716 | fastq.gz | 4.4 GB | ||
| EGAF00004186717 | fastq.gz | 4.4 GB | ||
| EGAF00004186718 | fastq.gz | 4.6 GB | ||
| EGAF00004186719 | fastq.gz | 3.1 GB | ||
| EGAF00004186720 | fastq.gz | 3.4 GB | ||
| EGAF00004186721 | fastq.gz | 4.4 GB | ||
| EGAF00004186722 | fastq.gz | 4.1 GB | ||
| 64 Files (253.3 GB) | ||||